Literature DB >> 21039471

T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Jeffrey Babad1, Ari Geliebter, Teresa P DiLorenzo.   

Abstract

The non-obese diabetic (NOD) mouse model of autoimmune (type 1) diabetes has contributed greatly to our understanding of disease pathogenesis and has facilitated the development and testing of therapeutic strategies to combat the disease. Although the model is a valuable immunological tool in its own right, it reaches its fullest potential in areas where its findings translate to the human disease. Perhaps the foremost example of this is the field of T-cell antigen discovery, from which diverse benefits can be derived, including the development of antigen-specific disease interventions. The majority of NOD T-cell antigens are also targets of T-cell autoimmunity in patients with type 1 diabetes, and several of these are currently being evaluated in clinical trials. Here we review the journeys of these antigens from bench to bedside. We also discuss several recently identified NOD T-cell autoantigens whose translational potential warrants further investigation.
© 2010 The Authors. Immunology © 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21039471      PMCID: PMC2999797          DOI: 10.1111/j.1365-2567.2010.03362.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  94 in total

Review 1.  A comprehensive review of interventions in the NOD mouse and implications for translation.

Authors:  Lisl K M Shoda; Daniel L Young; Saroja Ramanujan; Chan C Whiting; Mark A Atkinson; Jeffrey A Bluestone; George S Eisenbarth; Diane Mathis; Aldo A Rossini; Scott E Campbell; Richard Kahn; Huub T C Kreuwel
Journal:  Immunity       Date:  2005-08       Impact factor: 31.745

2.  Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity.

Authors:  Anish Suri; James J Walters; Michael L Gross; Emil R Unanue
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

3.  Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling.

Authors:  Alexandra Zanin-Zhorov; Liora Cahalon; Guy Tal; Raanan Margalit; Ofer Lider; Irun R Cohen
Journal:  J Clin Invest       Date:  2006-06-08       Impact factor: 14.808

4.  Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis.

Authors:  Gabriel Nussbaum; Alexandra Zanin-Zhorov; Francisco Quintana; Ofer Lider; Irun R Cohen
Journal:  Int Immunol       Date:  2006-08-07       Impact factor: 4.823

5.  Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.

Authors:  Carl-David Agardh; Corrado M Cilio; AsaLinda Lethagen; Kristian Lynch; R David G Leslie; Mats Palmér; Robert A Harris; John A Robertson; Ake Lernmark
Journal:  J Diabetes Complications       Date:  2005 Jul-Aug       Impact factor: 2.852

6.  RegII is a beta-cell protein and autoantigen in diabetes of NOD mice.

Authors:  Werner Gurr; Margaret Shaw; Yanxia Li; Robert Sherwin
Journal:  Diabetes       Date:  2007-01       Impact factor: 9.461

7.  Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP.

Authors:  Balasubramanian Krishnamurthy; Nadine L Dudek; Mark D McKenzie; Anthony W Purcell; Andrew G Brooks; Shane Gellert; Peter G Colman; Leonard C Harrison; Andrew M Lew; Helen E Thomas; Thomas W H Kay
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

8.  Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice.

Authors:  Maki Nakayama; Norio Abiru; Hiroaki Moriyama; Naru Babaya; Edwin Liu; Dongmei Miao; Liping Yu; Dale R Wegmann; John C Hutton; John F Elliott; George S Eisenbarth
Journal:  Nature       Date:  2005-05-12       Impact factor: 49.962

9.  Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low-affinity peptide.

Authors:  Bingye Han; Pau Serra; Abdelaziz Amrani; Jun Yamanouchi; Athanasius F M Marée; Leah Edelstein-Keshet; Pere Santamaria
Journal:  Nat Med       Date:  2005-05-22       Impact factor: 53.440

10.  Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Authors:  Brian T Fife; Indira Guleria; Melanie Gubbels Bupp; Todd N Eagar; Qizhi Tang; Helene Bour-Jordan; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Jeffrey A Bluestone
Journal:  J Exp Med       Date:  2006-11-20       Impact factor: 14.307

View more
  24 in total

Review 1.  New and future immunomodulatory therapy in type 1 diabetes.

Authors:  James E Tooley; Frank Waldron-Lynch; Kevan C Herold
Journal:  Trends Mol Med       Date:  2012-02-17       Impact factor: 11.951

Review 2.  CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes.

Authors:  Kathryn Haskins; Anne Cooke
Journal:  Curr Opin Immunol       Date:  2011-09-12       Impact factor: 7.486

3.  Development and Characterization of a Preclinical Model for the Evaluation of CD205-Mediated Antigen Delivery Therapeutics in Type 1 Diabetes.

Authors:  Jennifer Schloss; Riyasat Ali; Jeffrey Babad; Ignacio Guerrero-Ros; Jillamika Pongsachai; Li-Zhen He; Tibor Keler; Teresa P DiLorenzo
Journal:  Immunohorizons       Date:  2019-06-26

Review 4.  Novel autoantigens for diabetogenic CD4 T cells in autoimmune diabetes.

Authors:  Thomas Delong; Rocky L Baker; Jing He; Kathryn Haskins
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

Review 5.  Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Diab Rep       Date:  2017-08-08       Impact factor: 4.810

6.  Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes.

Authors:  I Gómez-Touriño; R Simón-Vázquez; J Alonso-Lorenzo; S Arif; C Calviño-Sampedro; Á González-Fernández; E Pena-González; J Rodríguez; J Viñuela-Roldán; J Verdaguer; O J Cordero; M Peakman; R Varela-Calvino
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

7.  Pharmacological inhibition of myostatin/TGF-β receptor/pSmad3 signaling rescues muscle regenerative responses in mouse model of type 1 diabetes.

Authors:  Jaemin Jeong; Michael J Conboy; Irina M Conboy
Journal:  Acta Pharmacol Sin       Date:  2013-06-17       Impact factor: 6.150

8.  Local autoantigen expression as essential gatekeeper of memory T-cell recruitment to islet grafts in diabetic hosts.

Authors:  Gonnie M Alkemade; Xavier Clemente-Casares; Zhenguo Yu; Bao-You Xu; Jinguo Wang; Sue Tsai; James R Wright; Bart O Roep; Pere Santamaria
Journal:  Diabetes       Date:  2012-11-16       Impact factor: 9.461

9.  Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells.

Authors:  Thomas Delong; Rocky L Baker; Nichole Reisdorph; Richard Reisdorph; Roger L Powell; Michael Armstrong; Gene Barbour; Brenda Bradley; Kathryn Haskins
Journal:  Diabetes       Date:  2011-07-06       Impact factor: 9.461

10.  Vaccination with single chain antigen receptors for islet-derived peptides presented on I-A(g7) delays diabetes in NOD mice by inducing anergy in self-reactiveT-cells.

Authors:  Werner Gurr; Margaret Shaw; Raimund I Herzog; Yanxia Li; Robert Sherwin
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.